Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[View FULLTEXT] [Download PDF
Year : 2009  |  Volume : 55  |  Issue : 4  |  Page : 296-300  


N Joshi, K Rajeshwari 
 Department of Pediatrics, Maulana Azad Medical College, New Delhi - 110 002, India

Correspondence Address:
N Joshi
Department of Pediatrics, Maulana Azad Medical College, New Delhi - 110 002

Conventional oral steroids like prednisolone have various adverse effects both during short-term and long-term use. Hence a search for an alternative oral steroid with fewer side-effects is underway throughout the world. Deflazacort, an oxazoline derivative, is a step in this direction. The number of large randomized trials using deflazacort for steroid-responsive disorders in children is limited. Use of deflazacort has been explored largely in patients with Duchenne«SQ»s muscular dystrophy. Preliminary data suggest reduced osteoporosis, lesser growth retardation and weight gain with use of deflazacort, as compared to other steriods. In view of the limited data demonstrating superiority of deflazacort over the available oral steroids and its prohibitive cost, it is early to advocate widespread use of this drug in children.

How to cite this article:
Joshi N, Rajeshwari K. Deflazacort.J Postgrad Med 2009;55:296-300

How to cite this URL:
Joshi N, Rajeshwari K. Deflazacort. J Postgrad Med [serial online] 2009 [cited 2022 Aug 13 ];55:296-300
Available from:;year=2009;volume=55;issue=4;spage=296;epage=300;aulast=Joshi;type=0

Saturday, August 13, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer